What's in Shanghai Cell Therapy Group Co.,Ltd's pipeline?

Shanghai Cell Therapy Group Co.,Ltd has 4 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Shanghai Cell Therapy Group Co.,Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-cell-therapy-group-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shanghai Cell Therapy Group Co.,Ltd — Portfolio Competitive Intelligence Brief

Shanghai Cell Therapy Group Co.,Ltd pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NMN	NMN	marketed	NAD+ precursor / metabolic supplement	NAD+ biosynthesis pathway	Aging / Metabolic Health / Longevity

Therapeutic area mix

Aging / Metabolic Health / Longevity · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Cell Therapy Group Co.,Ltd:

Cite this brief

Drug Landscape (2026). Shanghai Cell Therapy Group Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-cell-therapy-group-co-ltd. Accessed 2026-05-16.